Lexaria Bioscience Corp.
156 Valleyview Road
Kelowna
British Columbia
V1X3M4
United States
Tel: 250-765-6424
Website: http://www.lexariaenergy.com
About Lexaria Bioscience Corp.
Lexaria Bioscience Corp. is a food biosciences company with a proprietary technology for improved delivery of bioactive compounds. The Company's lipophilic enhancement technology has been shown to enhance the bioavailability of orally ingested cannabinoids, while also improving taste. This technology promotes healthy ingestion methods, lower overall dosing and higher effectiveness in active molecule delivery. The Company's technology is patent-protected for cannabidiol (CBD) and all other non-psychoactive cannabinoids, and patent-pending for Tetrahydrocannabinol (THC), other psychoactive cannabinoids, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules.YEAR FOUNDED:
2004
LEADERSHIP:
CEO: Chris Bunka
FOLLOW LEXARIA BIOSCIENCE:
Tweets by Lexaria Bioscience
100 articles about Lexaria Bioscience Corp.
-
Lexaria Bioscience Corp. Announces Closing of $11 Million Public Offering with Full Exercise of Underwriter Option to Purchase Additional Shares and Warrants
1/15/2021
Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX)) today announced the closing of its previously announced underwritten public offering (the of 1,828,571 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock at a public offering price of $5.25 per unit (all prices in US$).
-
Lexaria Bioscience Corp. Announces Uplisting to Nasdaq Capital Market and Pricing of $9.6 Million Upsized Public Offering
1/12/2021
Lexaria Bioscience Corp. today announced that its common stock and warrants will begin trading on the Nasdaq Capital Market on January 12, 2021, under the symbols and respectively.
-
Lexaria Announces Effective Date for Reverse Stock Split
1/8/2021
Lexaria Bioscience Corp. (OTCQX:LXRP)(CSE:LXX); or a global innovator in drug delivery platforms, today announced that it intends to effect a reverse stock split of its common stock effective as of 4:30 pm EST on January 11, 2021
-
Lexaria Expands COVID-19 Drug Research Program Utilizing Proprietary DehydraTECH
12/22/2020
Lexaria Bioscience Corp. (OTCQX:LXRP)(CSE:LXX) (the a global innovator in drug delivery platforms, today announced that it has initiated the next phase of its antiviral drug research program following successful results from a recent animal study announced on December 1, 2020.
-
Lexaria Closes Sale of Non-Pharmaceutical THC-Related Assets
12/10/2020
Lexaria Bioscience Corp. (OTCQX:LXRP)(CSE:LXX) (the , a global innovator in drug delivery platforms, announces that it has closed the sale of its non-pharmaceutical THC-related assets held within Lexaria Canpharm ULC, a Lexaria wholly-owned subsidiary, to Hill Street Beverage Company Inc.
-
Lexaria to Highlight its DehydraTECHTM Technology at Four Upcoming Investor Conferences
12/7/2020
Lexaria Bioscience Corp., a global innovator in drug delivery platforms, announced that its Chairman & CEO Chris Bunka is scheduled to present at four upcoming investor conferences in December 2020 and January 2021.
-
Lexaria’s Patented Technology Significantly Enhances Oral Delivery of Antiviral Drugs
12/1/2020
Demonstrates Improved Delivery of Two Classes of Drugs in Use Against HIV/AIDS and under investigation Against SARS-CoV-2/COVID-19
-
Lexaria Bioscience Sells Non-Pharmaceutical THC-Related Assets for CDN$3.85M
11/19/2020
Lexaria Bioscience Corp., a global innovator in oral drug delivery platforms, has entered a definitive asset purchase agreement, through its wholly owned subsidiary Lexaria Canpharm ULC, to sell certain non-core, non-pharmaceutical THC-related business assets for gross proceeds of $3.85 million CDN.
-
Lexaria Bioscience Advances 2021 Strategic Initiatives
11/5/2020
Lexaria Bioscience Corp., a global innovator in oral drug delivery platforms, is pleased to outline its planned strategic initiatives for 2021 with a sharply enhanced focus on solutions related to the regulated pharmaceutical and medical market segments where it believes its patented technology will offer the highest value and utility.
-
Lexaria Proprietary DehydraTECH-Enabled CBD Powders Business Growing Faster than Expected
10/22/2020
Lexaria Bioscience Corp., a global innovator in oral drug delivery platforms, is pleased to announce that it is exceeding expectations for volume of servings of its patented DehydraTECHTM enabled CBD powders, to be processed during the Company's fiscal Q1 2021 ending November 30, 2020.
-
Lexaria Bioscience Granted First European Patent for DehydraTECH Technology
10/21/2020
Lexaria Bioscience Corp., a global innovator in oral drug delivery platforms, is pleased to announce that it is receiving its first-ever granted patent in Europe related to its DehydraTECHTM technology.
-
Lexaria Receives Conditional Ethics Board Approval for Pilot Human Study Using DehydraTECH Technology in Delivering Antiviral Drugs
9/29/2020
Company Raises Commitment to Antiviral Research with Launch of Rodent Antiviral Drug Delivery Study with Potential COVID-19 Applications
-
Lexaria Receives Orders for 4.4 Million Servings of DehydraTECH-Enabled CBD Powders
9/23/2020
Lexaria Bioscience Corp. is pleased to announce that it is in receipt of purchase-order commitments for approximately 4.4 million CBD servings of its patented DehydraTECHTM enabled CBD powders,
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 19, 2020.
-
Lexaria Bioscience Corp. to Webcast Live at Life Sciences Investor Forum March 26
3/24/2020
Company invites individual and institutional investors, as well as advisors and analysts, to attend real-time, interactive presentations on LifeSciencesInvestorForum.com
-
Lexaria Bioscience Corp to Webcast Live at VirtualInvestorConferences.com July 11th
7/9/2019
Lexaria Bioscience Corp (LXRP:OTCQX LXX:CSE), based in Kelowna, BC, focused on the improved delivery of active pharmaceutical ingredients in food, beverages and topicals, today announced that Chris Bunka, CEO will present live at VirtualInvestorConferences.com on July 11th.
-
Lexaria Bioscience Receives Groundbreaking U.S. Patent Allowance for Its DehydraTECHTM Delivery of THC, NSAIDs, Nicotine and Vitamins.
11/1/2017
This Notice of Allowance applies to the delivery of all active pharmacological ingredients (“APIs”) Lexaria had been seeking.
-
Lexaria Bioscience Corp. Engages NetworkNewsWire For Corporate Communications Solutions
8/7/2017
-
National Research Council of Canada And Lexaria Bioscience Corp. Commence Laboratory Work
7/21/2017
-
Lexaria Bioscience Corp. Notice Of Patent In Australia For Cannabinoid Infused Edibles
2/28/2017